Volition Appoints Dr. Phillip Barnes to Board of Directors

VolitionRx Limited announced the appointment of Dr. Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effective October 9, 2019. Dr. Barnes was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. As a non-executive member of the Company's Board, Dr. Barnes will provide independent expertise and strategic counsel to VolitionRx in connection with the planned commercialization of its Nu.QTM blood-based diagnostic platform.

Martin Faulkes, Executive Chairman of Volition commented, "We are thrilled to have Dr. Barnes on our Board. His extensive clinical background and management expertise will make him a valuable asset and resource as we prepare for the launch of our Nu.QTM platform."

Dr. Barnes is a British physician with extensive experience both as a clinician and clinical manager within the UK National Health Service ("NHS") and related academic institutions. Dr. Barnes was also involved in a number of national and regional advisory groups for the Department of Health, NHS and pharmaceutical industry including being the national lead for the NHS Action On Neurology service modernization program. Dr. Barnes served as Executive Medical Director on a number of hospital and Foundation Trust Boards until his retirement from the NHS in 2016. Dr. Barnes holds a BSc and PhD from the University of London and his clinical medical degree (BM BCh) from the University of Oxford.

On joining the Volition Board Dr. Barnes commented, "I am delighted to join the Volition team as the company nears commercialization of what I believe will be a revolutionary technology. The Nu.QTM platform will be simple, cost effective and could provide an accessible test to millions of people around the world."

Dr. Barnes replaces Dr. Habib Skaff from the Volition Board, who resigned effective October 9, 2019. We would like to thank Dr. Skaff for his contributions to the company.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.